These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
315 related articles for article (PubMed ID: 30093562)
1. Loss of MST/Hippo Signaling in a Genetically Engineered Mouse Model of Fusion-Positive Rhabdomyosarcoma Accelerates Tumorigenesis. Oristian KM; Crose LES; Kuprasertkul N; Bentley RC; Lin YT; Williams N; Kirsch DG; Linardic CM Cancer Res; 2018 Oct; 78(19):5513-5520. PubMed ID: 30093562 [TBL] [Abstract][Full Text] [Related]
8. PAX3-FOXO1 is essential for tumour initiation and maintenance but not recurrence in a human myoblast model of rhabdomyosarcoma. Pandey PR; Chatterjee B; Olanich ME; Khan J; Miettinen MM; Hewitt SM; Barr FG J Pathol; 2017 Apr; 241(5):626-637. PubMed ID: 28138962 [TBL] [Abstract][Full Text] [Related]
10. Sphingosine Induces Apoptosis and Down-regulation of Ahn EH; Lee MB; Seo DJ; Lee J; Kim Y; Gupta K Anticancer Res; 2018 Jan; 38(1):71-76. PubMed ID: 29277758 [TBL] [Abstract][Full Text] [Related]
11. Targeting KDM4 for treating PAX3-FOXO1-driven alveolar rhabdomyosarcoma. Singh S; Abu-Zaid A; Jin H; Fang J; Wu Q; Wang T; Feng H; Quarni W; Shao Y; Maxham L; Abdolvahabi A; Yun MK; Vaithiyalingam S; Tan H; Bowling J; Honnell V; Young B; Guo Y; Bajpai R; Pruett-Miller SM; Grosveld GC; Hatley M; Xu B; Fan Y; Wu G; Chen EY; Chen T; Lewis PW; Rankovic Z; Li Y; Murphy AJ; Easton J; Peng J; Chen X; Wang R; White SW; Davidoff AM; Yang J Sci Transl Med; 2022 Jul; 14(653):eabq2096. PubMed ID: 35857643 [TBL] [Abstract][Full Text] [Related]
12. Reduced B7-H3 expression by PAX3-FOXO1 knockdown inhibits cellular motility and promotes myogenic differentiation in alveolar rhabdomyosarcoma. Kanayama T; Miyachi M; Sugimoto Y; Yagyu S; Kikuchi K; Tsuchiya K; Iehara T; Hosoi H Sci Rep; 2021 Sep; 11(1):18802. PubMed ID: 34552155 [TBL] [Abstract][Full Text] [Related]
13. Validation of met as a therapeutic target in alveolar and embryonal rhabdomyosarcoma. Taulli R; Scuoppo C; Bersani F; Accornero P; Forni PE; Miretti S; Grinza A; Allegra P; Schmitt-Ney M; Crepaldi T; Ponzetto C Cancer Res; 2006 May; 66(9):4742-9. PubMed ID: 16651427 [TBL] [Abstract][Full Text] [Related]
14. PAX3-FOXO1 drives miR-486-5p and represses miR-221 contributing to pathogenesis of alveolar rhabdomyosarcoma. Hanna JA; Garcia MR; Lardennois A; Leavey PJ; Maglic D; Fagnan A; Go JC; Roach J; Wang YD; Finkelstein D; Hatley ME Oncogene; 2018 Apr; 37(15):1991-2007. PubMed ID: 29367756 [TBL] [Abstract][Full Text] [Related]
15. Phosphorylation of serine 205 by the protein kinase CK2 persists on Pax3-FOXO1, but not Pax3, throughout early myogenic differentiation. Dietz KN; Miller PJ; Hollenbach AD Biochemistry; 2009 Dec; 48(49):11786-95. PubMed ID: 19904978 [TBL] [Abstract][Full Text] [Related]
16. PAX3-FOXO1 and FGFR4 in alveolar rhabdomyosarcoma. Marshall AD; van der Ent MA; Grosveld GC Mol Carcinog; 2012 Oct; 51(10):807-15. PubMed ID: 21882254 [TBL] [Abstract][Full Text] [Related]
17. Interleukin-24 (IL24) Is Suppressed by PAX3-FOXO1 and Is a Novel Therapy for Rhabdomyosarcoma. Lacey A; Hedrick E; Cheng Y; Mohankumar K; Warren M; Safe S Mol Cancer Ther; 2018 Dec; 17(12):2756-2766. PubMed ID: 30190424 [TBL] [Abstract][Full Text] [Related]
18. Structural and functional studies of FKHR-PAX3, a reciprocal fusion gene of the t(2;13) chromosomal translocation in alveolar rhabdomyosarcoma. Hu Q; Yuan Y; Wang C PLoS One; 2013; 8(6):e68065. PubMed ID: 23799156 [TBL] [Abstract][Full Text] [Related]